MedTrace Logo

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

NCT01539473 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-05-03

No results posted yet for this study

Summary

Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine

Conditions

  • Healthy Volunteers

Interventions

DRUG

TR-701 FA with Tyramine

TR-701 FA 200 mg oral and Tyramine

DRUG

Placebo-controlled withTyramine

Placebo-controlled and Tyramine

Sponsors & Collaborators

  • Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Philippe G Prokocimer, MD · Trius Therapeutics

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01539473 on ClinicalTrials.gov